(Q41209346)

28 September 2017

1 reference

title

Cytokine inhibitors in autoimmune disease (English)

1 reference

28 September 2017

1 reference

Weckmann AL

1

1 reference

PubMed ID

8916298

28 September 2017

Alcocer-Varela J

series ordinal

2

1 reference

28 September 2017

1 October 1996

1 reference

28 September 2017

19

1 reference

Seminars in Arthritis and Rheumatism

inferred from page(s)

published in

1 reference

28 September 2017

26

1 reference

28 September 2017

2

1 reference

28 September 2017

539-557

1 reference

Cytokine antagonists and their potential therapeutic use

28 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Native interleukin 1 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

The role of cytokines and their inhibitors in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Human monocytes produce IL-1 and an inhibitor of IL-1 in response to two different signals

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Interleukin 1 receptor antagonist. A new member of the interleukin 1 family

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Therapeutic modulation of cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Cellular signals for the induction of human interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Refined crystal structure of the interleukin-1 receptor antagonist. Presence of a disulfide link and a cis-proline

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Exclusion of Interleukin-1 Receptor Antagonist as a Primary Disease Determinant for Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

The M20 IL-1 inhibitor. II. Biological characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

The effect of human myelomonocytic leukemic cell line (M20) derived IL-1 inhibitor on human erythroid cell development

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

In vivo anti inflammatory effects of the M20 IL-1 inhibitor: I. Effects on acute inflammatory parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

In vivo anti-inflammatory effects of the M20 IL-1 inhibitor: II. Effects on serum reactants

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Regulation of tumor necrosis factor (TNF)-alpha synthesis and TNF receptors expression in T lymphocytes through the CD2 activation pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production b

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-β

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Cytokines in autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Immunoregulatory role of interleukin 10 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

DAB486IL-2 fusion toxin in refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

Soluble cytokine receptors: their role in immunoregulation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980042-4

7 January 2021

10.1016/S0049-0172(96)80042-4

Identifiers

DOI

1 reference

28 September 2017

1 reference

PubMed ID

8916298